1. Sufentanil Protects the Liver from Ischemia/Reperfusion-Induced Inflammation and Apoptosis by Inhibiting ATF4-Induced TP53BP2 Expression
   Ling Zhou et al, 2021, Inflammation CrossRef
2. Sufentanil inhibits the metastasis and immune response of breast cancer via mediating the NF-κB pathway
   Mingming Li et al, 2023, Immunopharmacology and Immunotoxicology CrossRef
3. Effects of Dexmedetomidine on Immune Cells: A Narrative Review
   Rui Chen et al, 2022, Frontiers in Pharmacology CrossRef
4. Trial watch: dexmedetomidine in cancer therapy
   Killian Carnet Le Provost et al, 2024, OncoImmunology CrossRef
5. Effect of dexmedetomidine on postoperative systemic inflammation and recovery in patients undergoing digest tract cancer surgery: A meta-analysis of randomized controlled trials
   Wenjie Xu et al, 2022, Frontiers in Oncology CrossRef
6. Analgesic Effects and Safety of Dexmedetomidine Added to Nalbuphine or Sufentanil Patient-Controlled Intravenous Analgesia for Children After Tonsillectomy Adenoidectomy
   Yingping Jia et al, 2022, Frontiers in Pharmacology CrossRef
7. Dexmedetomidine promotes autophagy and apoptosis of colon cancer cells by activating endoplasmic reticulum (ER) stress-mediated PERK/eIF2α/ATF4 signaling pathway
   Xiaochao Hou et al, 2023, Molecular & Cellular Toxicology CrossRef
8. Sufentanil inhibits Pin1 to attenuate renal tubular epithelial cell ischemia–reperfusion injury by activating the PI3K/AKT/FOXO1 pathway
   Chunhui Liu et al, 2023, International Urology and Nephrology CrossRef
9. Sufentanil Inhibits the Proliferation and Metastasis of Esophageal Cancer by Inhibiting the NF-κB and Snail Signaling Pathways
   Huiyan Tang et al, 2021, Journal of Oncology CrossRef
10. Sufentanil inhibits the proliferation and epithelial mesenchymal transition of lung cancer cells through Wnt/beta-catenin signaling pathway
    Minghan Guan et al, 2022, Bioengineered CrossRef